BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/23/2022 2:39:01 PM | Browse: 700 | Download: 1816
 |
Received |
|
2022-01-12 07:27 |
|
Peer-Review Started |
|
2022-01-12 07:28 |
|
First Decision by Editorial Office Director |
|
2022-03-16 03:17 |
|
Return for Revision |
|
2022-03-16 03:17 |
|
Revised |
|
2022-03-18 06:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-23 03:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-05-28 07:12 |
|
Articles in Press |
|
2022-05-28 07:12 |
|
Edit the Manuscript by Language Editor |
|
2022-05-17 23:11 |
|
Typeset the Manuscript |
|
2022-05-30 07:40 |
|
Publish the Manuscript Online |
|
2022-06-23 14:39 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kazuto Tajiri, Hiroyuki Ito, Kengo Kawai, Yoshiro Kashii, Yuka Hayashi, Aiko Murayama, Masami Minemura, Terumi Takahara, Yukihiro Shimizu and Ichiro Yasuda |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kazuto Tajiri, MD, PhD, Associate Professor, Department of Gastroenterology, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Japan. tajikazu@med.u-toyama.ac.jp |
| Key Words |
Direct acting antivirals; Hepatitis C virus; Hepatocellular carcinoma; Recurrence; Liver fibrosis; Curative treatment |
| Core Tip |
To estimate the therapeutic value of direct-acting antivirals (DAA) in hepatitis C virus (HCV)-infected patients with a history of hepatocellular carcinoma (HCC), the clinical course of HCV patients with or without a history of HCC after DAA therapy was retrospectively analyzed. DAA treatment did not increase the incidence rate of HCC recurrence/occurrence or enhance malignant transformation of HCC in patients with a history of HCC. The risk of HCC recurrence after DAA therapy was significantly associated with the frequency of HCC recurrence/occurrence before DAA therapy. |
| Publish Date |
2022-06-23 14:39 |
| Citation |
Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. World J Hepatol 2022; 14(6): 1190-1199 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i6/1190.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i6.1190 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
